Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Interpace Biosciences's total debt was $1.34M at Mar 31, 2024. For fiscal 2023 it was $4.24M, down 63.9% from the year before. The highest annual figure on record is $27.15M in fiscal 2014.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.24M | -63.9% |
| FY2022 | Dec 31, 2022 | $11.74M | +816.0% |
| FY2021 | Dec 31, 2021 | $1.28M | -73.7% |
| FY2020 | Dec 31, 2020 | $4.88M | +15.7% |
| FY2019 | Dec 31, 2019 | $4.22M | -46.6% |
| FY2016 | Dec 31, 2016 | $7.91M | -5.8% |
| FY2015 | Dec 31, 2015 | $8.40M | -69.1% |
| FY2014 | Dec 31, 2014 | $27.15M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | $1.34M | -88.5% |
| Q4 FY2023 | Dec 31, 2023 | $4.24M | -63.9% |
| Q3 FY2023 | Sep 30, 2023 | $11.57M | +1257.4% |
| Q2 FY2023 | Jun 30, 2023 | $11.31M | +201.8% |
| Q1 FY2023 | Mar 31, 2023 | $11.67M | +189.1% |
| Q4 FY2022 | Dec 31, 2022 | $11.74M | +816.0% |
| Q3 FY2022 | Sep 30, 2022 | $852.00K | -80.4% |
| Q2 FY2022 | Jun 30, 2022 | $3.75M | -11.1% |
| Q1 FY2022 | Mar 31, 2022 | $4.04M | -9.9% |
| Q4 FY2021 | Dec 31, 2021 | $1.28M | -73.7% |
| Q3 FY2021 | Sep 30, 2021 | $4.36M | -13.3% |
| Q2 FY2021 | Jun 30, 2021 | $4.22M | -20.7% |
| Q1 FY2021 | Mar 31, 2021 | $4.48M | +55.6% |
| Q4 FY2020 | Dec 31, 2020 | $4.88M | +15.7% |
| Q3 FY2020 | Sep 30, 2020 | $5.02M | +9.7% |
| Q2 FY2020 | Jun 30, 2020 | $5.32M | +21.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.88M | -63.6% |
| Q4 FY2019 | Dec 31, 2019 | $4.22M | -53.2% |
| Q3 FY2019 | Sep 30, 2019 | $4.58M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.36M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.91M | – |
| Q3 FY2016 | Sep 30, 2016 | $9.02M | – |
See a number that looks wrong?